- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03418155
Efficacy and Safety of TongBi Capsule in Patients With Knee Osteoarthritis
Efficacy and Safety of TongBi Capsule in Patients With Knee Osteoarthritis:a Randomized, Double-blind, Placebo-controlled Post - Market Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Jiang Quan
- Phone Number: 86-010-88001060
- Email: doctorjq@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100052
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1.45-75 years of age (including 45 years and 75 years old), men and women are not limited.
2. western medicine diagnosis of knee osteoarthritis, clinical classification for primary.
3.The severity of the imaging classification of K-L≤Ⅲ; 4. treatment VAS pain scores than 40mm (select the subjects most obvious limb pain symptoms).
5. informed consent form signed by the patient or legal representative.
Exclusion Criteria:
- within 3 months prior to the trial, the patients were treated within intra-articular treatment.
- 4 weeks before the treatment, corticosteroids, non steroidal drugs, intra-articular injections or other drugs to improve the condition (such as cartilage protective agents) were used.
The screening period has any disease history or evidence:
The basic of serious cardiovascular and cerebrovascular diseases; An active, recurrent peptic ulcer or other hemorrhagic disease risk; Sales and other serious diseases of digestive system; An associated with malignant tumors, blood, or other serious diseases or system; Patients who are unable to cooperate or cooperate with other mental disorders.
Before the screening, any laboratory test indicators meet the following standards:
An admission of liver and kidney function showed that ALT and AST is more than 1.5 times the upper limit of the normal value, Cr is more than 1.2 times the upper limit of normal (Reference Research Center laboratory where the range of normal value); An other clinically significant laboratory abnormalities, and the researchers judged not into the group.
- Allergic constitution or allergic to TongBi capsul, excipients or similar ingredients;
- Professional athletes;
- doubt or indeed history of alcohol and drug abuse;
- participants who participated in other clinical trials within the first 3 months;
- the researchers believe that patients should not participate in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment of TongBi Capsule
|
TongBi Capsule:0.31g,3times
a day, oral, for 4 weeks.
Other Names:
|
Placebo Comparator: Treatment of TongBi Placebo
|
TongBi placebo:0.31g,3times
a day, oral, for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change from Baseline to week 4 in Visual Analog Scale (VAS)score
Time Frame: 0 weeks,2 weeks,4 weeks
|
VAS scores ranges from 0 to 100, with higher scores indicating heavier pain
|
0 weeks,2 weeks,4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of adverse events
Time Frame: 4 weeks
|
The number of adverse events related to treatment.
|
4 weeks
|
The change from Baseline to week 4 in Western Ontarioand McMaster Universities
Time Frame: 0 weeks,2 weeks and 4 weeks
|
WOMAC scores ranges from 0 to 96, with higher scores indicating greater disability
|
0 weeks,2 weeks and 4 weeks
|
The change from baseline to week 4 in The Short Form-36 Health Survey (SF-36) scores
Time Frame: 0 weeks,4 weeks
|
SF-36 scores ranges from 0 to 100,it shows the extent of physical function
|
0 weeks,4 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jiang Quan, Guang'anmen Hospital of China Academy of Chinese Medical Sc
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BH_2016001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on Treatment of TongBi Capsule
-
Guang'anmen Hospital of China Academy of Chinese...UnknownKnee OsteoarthritisChina
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.UnknownAdvanced Solid TumorChina
-
Bristol-Myers SquibbRecruiting
-
Shanghai Changzheng HospitalUnknownTethered Cord SyndromeChina
-
AstraZenecaCompleted
-
Genentech, Inc.CompletedHealthy VolunteersUnited States
-
Sao Thai Duong Joint Stock CompanyBig Leap Clinical Research Joint Stock CompanyNot yet recruiting
-
University of UlsterUniversity of ReadingCompleted
-
Singapore Institute for Clinical SciencesRecruitingSleep | Stress Response | Cognition | Mood StateSingapore
-
Eastern Hepatobiliary Surgery HospitalSun Yat-sen University; Shanghai Zhongshan Hospital; First Affiliated Hospital... and other collaboratorsUnknownHepatocellular Carcinoma | Tumor Recurrence